TreatmentAcute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation
ManufacturerLUCIUS PHARMACEUTICAL,Laos PDR
Gilteritinib is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other therapies.
Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018. This drug was approved after being designed as an orphan drug with a fast track and priority review status.
Acute Myeloid Leukemia
- Indicated for treatment of patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation
- 120 mg PO qDay
- Response may be delayed
- Continue for at least 6 months for a clinical response or until disease progression or unacceptable toxicity